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Objectives The purpose of this study was to quantify the extent and complexity of residual coronary stenoses following per-
cutaneous coronary intervention (PCI) and to evaluate its impact on adverse ischemic outcomes.
Background Incomplete revascularization (IR) after PCI is common, and most studies have suggested that IR is associated
with a worse prognosis compared with complete revascularization (CR). However, formal quantification of the
extent and complexity of residual atherosclerosis after PCI has not been performed.
Methods The baseline Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score (bSS) from 2,686 angio-
grams from patients with moderate- and high-risk acute coronary syndrome (ACS) undergoing PCI enrolled in the
prospective ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial was determined. The SS
after PCI was also assessed, generating the “residual” SS (rSS). Patients with rSS 0 were defined as having IR
and were stratified by rSS tertiles, and their outcomes were compared to the CR group.
Results The bSS was 12.8  6.7, and after PCI the rSS was 5.6  2.2. Following PCI, 1,084 patients (40.4%) had
rSS  0 (CR), 523 (19.5%) had rSS 0 but 2, 578 (21.5%) had rSS 2 but 8, and 501 patients (18.7%) had
rSS 8. Age, insulin-treated diabetes, hypertension, smoking, elevated biomarkers or ST-segment deviation, and
lower ejection fraction were more frequent in patients with IR compared with CR. The 30-day and 1-year rates of
ischemic events were significantly higher in the IR group compared with the CR group, especially those with high
rSS. By multivariable analysis, rSS was a strong independent predictor of all ischemic outcomes at 1 year, in-
cluding all-cause mortality (hazard ratio: 1.05, 95% confidence interval: 1.02 to 1.09, p  0.006).
Conclusions The rSS is useful to quantify and risk-stratify the degree and complexity of residual stenosis after PCI. Specifi-
cally, rSS 8.0 after PCI in patients with moderate- and high-risk ACS is associated with a poor 30-day and 1-year
prognosis. (Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes; NCT00093158) (J Am Coll Cardiol
2012;59:2165–74) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.03.010Achieving complete revascularization (CR) is intuitively
desirable in patients with coronary artery disease undergoing
revascularization. However, despite major advances in per-
cutaneous coronary intervention (PCI), CR is often not
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Residual SYNTAX Score June 12, 2012:2165–74the extent, severity, and nature of
residual coronary stenoses after PCI
may have varying effects on patient
outcomes. Indeed, definitions of IR
in prior studies have varied accord-
ing to the degree of coronary steno-
sis severity (e.g., 50% vs. 70%)
or vessel size diameter (e.g.,1.5 to
2.5 mm) required to be treated
(3,4,7,8). Systematic characteriza-
tion and quantification of residual
atherosclerosis after PCI may there-
fore be important to standardize and
improve the prognostic utility of IR.
To our knowledge this issue has not
been previously addressed.
Since its first description (9), the
Synergy Between PCI With Taxus
and Cardiac Surgery (SYNTAX)
score (SS), a quantitative and
reproducible measure of baseline
(pre-revascularization) coronary
anatomic severity and complex-
ity, has been shown to offer in-
dependent prognostic utility in
patients undergoing PCI (10–
19). We therefore hypothesized
that the “residual” SS (rSS) after
CI would provide independent prognostic utility as a
uantitative measure of IR. We therefore sought to evaluate
he predictive value of IR according to the rSS following
CI in the multicenter, prospective randomized ACUITY
Acute Catheterization and Urgent Intervention Triage
trategY) trial.
ethods
tudy protocol. The ACUITY trial design has previously
een reported in detail (20). Briefly, the ACUITY trial was
multicenter, prospective, randomized trial of patients with
oderate- and high-risk acute coronary syndrome (ACS)
ho were managed with an early invasive strategy. Patients
ere randomly assigned before coronary angiography to
eparin (unfractionated or low molecular weight) plus a
lycoprotein IIb/IIIa inhibitor, bivalirudin plus a glyco-
rotein IIb/IIIa inhibitor, or bivalirudin monotherapy with
rovisional glycoprotein IIb/IIIa inhibitor use. Angiography
as performed within 72 h of randomization. Depending
n coronary anatomy, patients were then treated with PCI,
oronary artery bypass graft (CABG) surgery, or medical
herapy. In patients undergoing PCI, the choice of either
are-metal or drug-eluting stents was per operator discre-
ion. Dual antiplatelet therapy with aspirin and clopidogrel
as strongly recommended for at least 1 year. All major
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
bSS  baseline SYNTAX
score
CABG  coronary artery
bypass graft
CI  confidence interval
CR  complete
revascularization
IR  incomplete
revascularization
MACE  major adverse
cardiovascular event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
ROC  receiver-operating
characteristic
rSS  residual SYNTAX
score
SS  SYNTAX score
SYNTAX  Synergy
Between Percutaneous
Coronary Intervention With
Taxus and Cardiac Surgerydverse events were adjudicated by an independent clinical events committee blinded to treatment assignment and
rocedural outcomes.
bjectives, patient population, and angiographic analysis.
ur primary objective was to quantify the extent and
omplexity of residual coronary stenoses following PCI by
he rSS, and to evaluate its impact on adverse ischemic
utcomes, including the 30-day and 1-year rates of all-cause
eath, cardiac death, myocardial infarction (MI), and un-
lanned repeat revascularization for ischemia. We included
nly the subgroup of PCI patients in whom core laboratory-
ased quantitative coronary angiography was performed
linded to treatment assignment and clinical outcomes in
he formal angiographic substudy of the ACUITY trial (21).
s the SS score has been validated only for patients with
ative coronary artery disease, patients with a history of
ABG were excluded.
For the present study, the baseline SS (bSS) was assessed
isually by 3 experienced interventional cardiologists,
rained for SS assessment, and blinded to treatment assign-
ent and clinical outcomes as previously described (22).
ach lesion with 50% diameter stenosis in vessels 1.5
m in diameter was scored using the SS algorithm fully
escribed elsewhere (9). All data were entered into a
edicated computerized database. Interobserver reproduc-
bility between the 3 readers was determined prior to the
eginning of this study (50 angiograms) and was at least
ubstantial (kappa 0.76, 95% confidence interval [CI]: 0.64
o 1.00). Intraobserver reproducibility for the SS was at least
oderate for all 3 readers (kappa 0.88, 95% CI: 0.60 to1.00;
appa 0.64, 95% CI: 0.43 to 0.86; kappa 0.66, 95% CI: 0.44
o 0.89, respectively) (22). The rSS was determined as the
S remaining after completion of PCI. In the case of staged
CI procedures, (defined as a second planned PCI proce-
ure after the initial intervention) the final planned proce-
ure was used as the entry point for this study.
ndpoints, definitions, and statistical analysis. CR was
efined as a post-PCI rSS  0. Patients with IR (rSS 1)
ere grouped in tertiles of rSS for analysis and compared to
hose with CR. Composite of major adverse cardiovascular
vents (MACE) was defined as death from any cause, MI,
r unplanned revascularization for ischemia. The compo-
ents of the MACE endpoint have been previously de-
cribed (20).
Continuous data are presented as mean  SD and were
ompared using the Student t test or the Mann-Whitney
ank sum test, as appropriate. Categorical variables were
ompared by the chi-square or the Fisher exact test. Thirty-
ay and 1-year outcomes were determined using Kaplan-
eier methodology and compared using the log-rank test.
o assess the association between rSS and 1-year rates of
ll-cause mortality, cardiac mortality, MI, unplanned revas-
ularization for ischemia, and MACE, stepwise Cox mul-
ivariable regression analyses were performed, with variable
ntry/stay criteria of 0.1/0.1. In addition to the rSS, vari-
bles historically known to be associated with these adverse
vents were included in the models, with the number
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June 12, 2012:2165–74 Residual SYNTAX Scorecarefully chosen to avoid overfitting. The proportional haz-
ards assumption was verified for each endpoint using the
supremum test. Receiver-operating characteristic (ROC)
curves for both bSS and rSS were performed and compared
using the nonparametric correlated ROC curves compassion
method (23) to assess the relative predictive accuracy for the
1-year ischemic endpoints. Statistical analyses were performed
using SAS version 9.1 (SAS Institute, Cary, North Carolina).
A p value 0.05 was considered statistically significant.
Results
Patients and baseline characteristics. Among the 6,921
patients enrolled in the ACUITY trial angiographic sub-
study, 3,826 patients underwent PCI. From this group,
1,140 patients were excluded from the present study because
of previous CABG surgery (n  862) or inability to
calculate the bSS or rSS for technical reasons (n  278).
Thus, paired bSS and rSS were available in 2,686 patients.
The mean bSS was 12.8  6.7 before PCI, ranging from 0
to 59.5. Following PCI, the mean rSS was 5.6  2.2,
ranging from 0 to 47.5. CR (rSS 0) was achieved in 1,084
patients (40.4%). Among patients with IR, by tertile group-
ing 523 patients (19.5%) had rSS 0 but 2 (mean 1.5 
0.5), 578 (21.5%) had rSS2 but8 (mean 5.2 1.6), and
501 patients (18.7%) had rSS 8 (mean 15.8  6.5). A
strong correlation was present between bSS and rSS, al-
though for any level of bSS, the range of post-PCI rSS
varied considerably (Fig. 1). Figure 2 shows the level of
completeness of revascularization stratified by the rSS ac-
cording to original bSS tertiles.
Clinical and angiographic characteristics of patients strat-
ified by rSS are shown in Table 1. Compared with patients
Figure 1 Correlation Between bSS and rSS
Relationship between the baseline SYNTAX score (bSS) (x-axis) and the residual S
Each point may represent more than 1 value. A strong correlation was present bet
siderably. SYNTAX  Synergy Between Percutaneous Coronary Intervention With Tawith CR, patients with IR were older, more likely to haveinsulin-treated diabetes, hypertension, baseline elevated
biomarkers or ST-segment deviation, lower left ventricle
ejection fraction, and higher Thrombolysis In Myocardial
Infarction risk score. Patients with IR were also more likely
to have more complex coronary disease, with higher SS at
baseline, with more triple-vessel disease, longer lesions, more
calcified lesions, and more thrombotic lesions. Thienopyridines
were less frequently used in the upper rSS group at discharge
and 30-day follow-up, but not at 1 year (Table 2).
SYNTAX score components in the IR groups. Table 3
shows the distribution of the SS variables present in each tertile
among patients with IR. The highest rSS tertile was signifi-
cantly more likely to contain nonrevascularized lesions that
were severely calcified, chronic total occlusions; bifurcation/
score (rSS) (y-axis) after percutaneous coronary intervention in 2,686 patients.
bSS and rSS, although for any level of bSS, the range of post-PCI rSS varied con-
nd Cardiac Surgery.
Figure 2 Completeness of Revascularization
Stratified by rSS According to bSS
Distribution of level of completeness of revascularization stratified by rSS score
according to bSS score. Complete revascularization was infrequent in the
2 upper tertiles of the bSS. Abbreviations as in Figure 1.YNTAX
ween
xus a
A
P
M
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Residual SYNTAX Score June 12, 2012:2165–74trifurcations; and 20 mm in length. Small vessel and diffuse
disease was common in all 3 tertiles of IR patients.
Clinical outcomes. The 30-day and 1-year rates of all
ischemic events were significantly higher in the IR
Baseline Characteristics According to rSSTable 1 Baseline Characteristics According to rSS
rSS  0
(n  1,084)
rS
(n
Age, yrs 59 (51–68) 59 (
Male 66.6% (722/1,084) 64.6% (
Weight, kg 88.0 (75.0–101.9) 85.0 (
Diabetes 25.0% (270/1,079) 28.9% (
Insulin-treated 6.4% (69/1,079) 9.4% (
Hypertension 62.0% (669/1079) 64.0% (
Hyperlipidemia 54.0% (576/1,067) 56.1% (
Current smoker 35.8% (387/1,081) 37.9% (
Previous MI 25.7% (273/1,063) 28.7% (
Previous PTCA 44.0% (477/1,083) 45.5% (
Renal insufficiency* 14.0% (143/1,019) 14.9% (
Baseline cardiac biomarker elevation 57.5% (583/1,014) 57.7% (
Baseline troponin elevation 59.8% (553/925) 57.5% (
ST-segment deviation 1 mm 25.3% (274/1,084) 22.9% (
Baseline cardiac biomarker elevation or
ST-segment deviation
67.0% (692/1,033) 66.6% (
TIMI risk score
Low (0–2) 18.1% (157/866) 17.8% (
Intermediate (3–4) 61.0% (528/866) 61.3% (
High (5–7) 20.9% (181/866) 20.8% (
Ejection fraction, % 66.70 (59.00–73.50) 67.50 (
Ejection fraction 35% 0.6% (4/718) 0.9% (
Number with 2-vessel CAD 40.6% (440/1,084) 41.9% (
Number with 3-vessel CAD 25.2% (273/1,084) 35.8% (
Lesions per patient 3.01 1.79 (1,083) 3.46
PCI vessel
LAD 41.7% (602/1,444) 39.2% (
RCA 31.7% (458/1,444) 32.8% (
LCX 26.6% (384/1,444) 28.0% (
Lesion severity
MACC B1 31.5% (455/1,444) 28.3% (
MACC B2 22.0% (318/1,444) 20.9% (
MACC C 34.7% (501/1,444) 36.2% (
Lesion length 20 mm 18.3% (259/1,417) 19.2% (
Moderate/severe tortuosity 2.3% (33/1,442) 1.9% (
Severe calcification 3.1% (44/1,413) 1.4% (
Thrombus 1.4% (20/1,444) 1.7% (
Ulceration 3.4% (49/1,439) 5.1% (
Aneurysm 1.3% (18/1,440) 0.3% (
Ectasia 5.0% (72/1,440) 4.5% (
Drug-eluting stent 86.9% (942/1,084) 84.6% (
Bare-metal stent 12.0% (130/1,084) 15.0% (
Baseline SYNTAX score 7.5 5.6 9.3
Residual SYNTAX score 0 1.5
Delta† SYNTAX score 7.3 5.4 7.5
Values are median (IQR), % (n/N), or mean SD (N). *Renal insufficiency is defined as a calculated
represents the burden of disease removed by PCI.
CAD  coronary artery disease; IQR  interquartile range; LAD  left anterior descending a
ssociation stenosis morphology classification; MI  myocardial infarction; PTCA  percutaneo
ercutaneous Coronary Intervention With Taxus and Cardiac Surgery score; SYNTAX Synergy B
yocardial Infarction.compared with CR groups and across all the rSS tertiles(Table 4, Fig. 3). By multivariable analysis, rSS was a
strong independent predictor of all ischemic outcomes at
1 year, including all-cause mortality (Table 5).
ROC curves analysis. ROC curve analysis demonstrated a
2
3)
rSS >2–8
(n  578)
rSS >8
(n  501)
p Value
All Groups
) 61 (53–69) 63 (55–72) 0.001
23) 70.4% (407/578) 68.7% (344/501) 0.17
8.0) 88.0 (77.0–101.0) 85.0 (75.0–98.0) 0.13
22) 31.3% (179/572) 34.1% (170/499) 0.01
2) 7.9% (45/572) 10.6% (53/499) 0.02
20) 70.9% (409/577) 70.3% (352/501) 0.001
15) 57.9% (329/568) 60.4% (300/497) 0.09
22) 35.0% (201/575) 31.1% (155/499) 0.13
13) 32.1% (181/564) 34.3% (169/492) 0.01
21) 46.0% (266/578) 41.1% (205/499) 0.37
1) 16.1% (87/540) 18.8% (86/457) 0.12
85) 58.9% (313/531) 68.5% (315/460) 0.001
57) 58.1% (289/497) 67.5% (295/437) 0.01
23) 26.1% (151/578) 27.3% (137/501) 0.41
94) 68.1% (368/540) 75.9% (356/469) 0.01
2) 14.5% (70/484) 11.6% (47/404) 0.01
32) 56.4% (273/484) 55.4% (224/404) 0.12
2) 29.1% (141/484) 32.9% (133/404) 0.001
73.80) 66.40 (58.90–72.50) 62.30 (53.10–71.80) 0.001
) 1.1% (4/356) 4.0% (13/325) 0.001
23) 36.6% (209/571) 27.4% (135/493) 0.001
23) 51.5% (294/571) 64.5% (318/493) 0.001
(523) 4.22 2.06 (568) 5.08 2.43 (493) 0.001
43) 36.9% (267/724) 21.0% (111/529) 0.001
43) 36.2% (262/724) 40.3% (213/529) 0.001
43) 26.9% (195/724) 38.8% (205/529) 0.001
43) 30.0% (217/724) 27.2% (144/529) 0.20
43) 21.8% (158/724) 18.1% (96/529) 0.28
43) 38.7% (280/724) 46.7% (247/529) 0.001
31) 22.3% (156/701) 26.8% (134/500) 0.001
1) 3.5% (25/719) 1.9% (10/528) 0.16
6) 2.9% (20/700) 5.2% (27/523) 0.01
1) 5.1% (40/778) 9.9% (62/624) 0.001
0) 4.9% (35/720) 5.9% (31/526) 0.06
) 1.5% (11/720) 1.0% (5/526) 0.08
1) 4.7% (34/720) 8.4% (44/525) 0.01
19) 86.8% (485/559) 78.5% (376/479) 0.001
9) 15.7% (88/559) 15.7% (75/479) 0.08
12.6 6.9 21.7 8.6 0.001
5.2 1.6 15.8 6.5 0.001
6.9 6.3 5.7 6.4 0.15
ine clearance rate60ml/min determined by the Cockcroft-Gault equation. †Delta SYNTAX score
X  left circumflex artery; MACC  Modified American College of Cardiology/American Heart
sluminal coronary angioplasty; RCA  right coronary artery; rSS  residual Synergy Between
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; TIMI  Thrombolysis InS >0–
 52
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338/5
75.0–9
151/5
49/52
333/5
289/5
198/5
147/5
237/5
73/49
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77/43
265/4
90/43
59.30–
3/335
219/5
187/5
1.83
291/7
244/7
208/7
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June 12, 2012:2165–74 Residual SYNTAX Scoremortality, cardiac mortality, MI, unplanned revasculariza-
tion for ischemia, and MACE. An rSS cutoff of 5 had the
best prognostic accuracy for risk prediction of death and
cardiac death (Table 6). When compared with the bSS, the
rSS had a similar predictive value and discrimination for
all-cause mortality (bSS AUC: 0.63, 95% CI: 0.55 to 0.70
vs. rSS AUC: 0.63, 95% CI: 0.56 to 0.70; p  0.92),
nplanned revascularization for ischemia (bSS AUC: 0.56,
5% CI: 0.52 to 0.59 vs. rSS AUC: 0.53, 95% CI: 0.50 to
.57; p  0.18), and MACE (bSS AUC: 0.57, 95% CI:
.54 to 0.60 vs. rSS AUC: 0.55, 95% CI: 0.53 to 0.58; p 
.16) at 1 year, whereas the bSS was a slightly stronger
redictor of MI (bSS AUC: 0.60, 95% CI: 0.57 to 0.64 vs.
SS AUC: 0.57, 95% CI: 0.53 to 0.60; p  0.03).
ompleteness of revascularization by bSS. Figure 4
hows the impact of CR versus IR on the 1-year rate of
Medical Therapies According to the rSSTable 2 Medical Therapies According to the rSS
rSS  0
(n  1,084)
rSS
(n 
Antiplatelet medications (pre-PCI)
Aspirin 98.6% (1,067/1,082) 98.1%
Thienopyridine 57.1% (617/1,081) 59.1%
Antithrombin medications
Bivalirudin 67.8% (735/1,084) 63.7%
Unfractionated heparin 19.6% (213/1,084) 17.6%
Enoxaparin 12.0% (130/1,084) 16.8%
Glycoprotein IIb/IIIa inhibitor used 67.1% (727/1,084) 68.1%
Discharge
Aspirin 89.2% (955/1,071) 86.1%
Thienopyridines 88.0% (943/1,071) 82.8%
30 days
Aspirin 97.1% (1,028/1,059) 98.0%
Thienopyridines 94.1% (996/1,059) 95.2%
Statins 84.4% (894/1,059) 82.9%
Beta-blockers 77.3% (819/1,059) 77.3%
ACE inhibitors 52.3% (554/1,059) 53.0%
1 year
Aspirin 91.5% (946/1,034) 90.5%
Thienopyridines 67.5% (697/1,033) 67.4%
Statins 79.4% (821/1,034) 77.1%
Beta-blockers 68.6% (709/1,034) 68.8%
ACE inhibitors 50.6% (523/1,034) 50.6%
Values are % (n/N).
ACE  angiotensin-converting enzyme; PCI  percutaneous coronary intervention; rSS  residu
rSS Components in Patients WithIncomplete Revascul rization According to TertTable 3 rSS Components in Patie ts WithIncomplete Revascularization Acco
rSS >0–2
(n  523)
Severe calcification 0 (0%)
Chronic total occlusion 1 (0.2%)
Bifurcation/trifurcation 0 (0%)
Aorto-ostial lesion 1 (0.2%)
Lesion length 20 mm 3 (0.6%)
Small vessel/diffuse disease* 409 (78.2%)Values are n (%). *Presence of at least 1 segment in the nonrevascularized v
rSS  residual Synergy Between Percutaneous Coronary Intervention Witheath according to the bSS tertiles of our cohort. In the
ower risk tertile (bSS 7), there were no significant
ifferences in the rates of 1-year mortality according to the
evel of completeness of revascularization (Fig. 4A). How-
ver, in the intermediate- (bSS 7 to 13) and high-risk tertile
bSS 13), IR with rSS 8 was associated with greater
ortality than CR (Figs. 4B and 4C).
iscussion
he current report, drawn from a large cohort of 2,686
atients with moderate- and high-risk ACS, is the first
tudy to quantify the extent and nature of coronary artery
isease prior to and following revascularization with PCI.
he major results of the present study are as follows: 1) the
SS is a novel instrument to quantify the extent and
)
rSS >2–8
(n  578)
rSS >8
(n  501)
p Value
All Groups
21) 98.6% (563/571) 98.0% (486/496) 0.72
18) 56.5% (322/570) 57.4% (284/495) 0.84
23) 64.9% (375/578) 62.7% (314/501) 0.15
3) 18.5% (107/578) 21.8% (109/501) 0.36
3) 12.8% (74/578) 13.4% (67/501) 0.06
23) 64.4% (372/578) 65.3% (327/501) 0.52
17) 89.2% (511/573) 87.4% (430/492) 0.25
17) 83.1% (476/573) 77.2% (380/492) 0.001
02) 96.4% (540/560) 96.3% (463/481) 0.35
02) 92.1% (516/560) 89.2% (429/481) 0.001
02) 81.1% (454/560) 83.5% (401/480) 0.38
02) 77.5% (434/560) 79.0% (379/480) 0.90
02) 57.4% (321/559) 61.3% (294/480) 0.001
84) 91.4% (502/549) 91.1% (418/459) 0.92
84) 69.0% (379/549) 66.4% (305/459) 0.84
84) 76.1% (418/549) 81.5% (374/459) 0.15
84) 71.0% (390/549) 70.6% (324/459) 0.70
84) 50.1% (275/549) 55.3% (254/459) 0.30
rgy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery score.
to Tertile
rSS >2–8
(n  578)
rSS >8
(n  501)
p Value
All Groups
10 (1.7%) 59 (11.8%) 0.001
58 (10.0%) 216 (43.1%) 0.001
179 (30.9%) 287 (57.3%) 0.001
4 (0.7%) 14 (0.3%) 0.001
143 (24.7%) 351 (70.1%) 0.001
303 (52.4%) 264 (52.7%) 0.001>0–2
523
(511/5
(306/5
(333/5
(92/52
(88/52
(356/5
(445/5
(428/5
(492/5
(478/5
(416/5
(388/5
(266/5
(438/4
(326/4
(373/4
(333/4
(245/4ile
rdingessel described as small vessel/diffuse disease.
Taxus and Cardiac Surgery score.
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and is a strong independent predictor of 1-year mortality,
cardiac mortality, MI, unplanned revascularization for isch-
emia, and MACE; 2) compared with the bSS, rSS had
similar prognostic accuracy for risk prediction of 1-year
mortality, unplanned revascularization for ischemia, and
MACE, but slightly less discrimination for risk prediction
of 1-year MI; and 3) despite a strong correlation being
present between the bSS and the rSS after PCI, the degree
of IR varied greatly for any baseline level of disease, which
has important prognostic implications.
Several studies have attempted to compare outcomes
between CR versus IR after PCI (1–5,7,24–27). However,
the retrospective nature of those studies, the small number
of patients enrolled, the lack of consensus on CR definition,
numerous statistical and methodological issues, and signif-
icant differences in patient populations studied has led to
conflicting results as to the prognostic importance of CR.
Recently, Aggarwal and colleagues showed in a meta-
analysis from 9 studies that CR by PCI was associated with
a marginally lower rate of death, MI, and need for CABG
at a mean follow-up of 29 months, with no difference in
repeat PCI, as compared with IR (28). Conversely, the only
randomized controlled trial comparing a strategy of culprit
vessel revascularization to CR failed to demonstrate supe-
riority of CR compared with IR regarding 30-day and
1-year rate of major outcomes, including mortality (29).
The lack of consensus among previous reports highlights
the need for better population characterization, baseline
30-Day and 1-Year Outcomes According to the rSSTable 4 30-Day and 1-Year Outcomes According to the rSS
rSS  0 (a) rSS >0–2 (b) rSS >2–8 (c) r
30-day outcomes
MACE 6.9% (75) 9.2% (48) 11.8% (68) 1
Death, all-cause 0.5% (5) 1.2% (6) 0.5% (3)
Cardiac 0.3% (3) 1.2% (6) 0.5% (3)
Myocardial infarction 4.9% (53) 7.7% (40) 8.8% (51)
Definite/probable stent
thrombosis
0.8% (8) 1.2% (6) 0.8% (3)
Death or myocardial
infarction
5.3% (57) 8.2% (43) 9.0% (52) 1
Unplanned revascularization
for ischemia
2.7% (29) 2.3% (12) 5.2% (30)
1-year outcomes
MACE 16.3% (167) 18.0% (92) 20.0% (113) 2
Death, all-cause 1.4% (15) 2.8% (14) 2.1% (12)
Cardiac 0.4% (4) 2.2% (11) 1.2% (7)
Myocardial infarction 7.1% (75) 9.7% (50) 10.4% (59) 1
Definite/probable stent
thrombosis
1.0% (11) 1.6% (8) 1.6% (6)
Death or myocardial
infarction
8.1% (86) 11.1% (57) 11.8% (67) 1
Unplanned revascularization
for ischemia
10.9% (109) 11.1% (55) 12.6% (70) 1
Event rates are Kaplan-Meier estimates, % (n).
MACE  major adverse cardiovascular event(s); rSS  residual Synergy Between Percutaneousdisease stratification, and residual disease quantification.Surprisingly, few prior studies have been performed to
determine whether the extent of IR is meaningful. Leaman
et al. (3), in 1981, were the first to attempt to predict
prognosis and recurrence of angina after revascularization
using a primitive scoring system of coronary artery disease
severity. Quantification of extension and severity of coro-
nary artery disease was assessed both at baseline and after
CABG (30). To account for revascularization of a given
diseased artery, the author decided to subtract from the baseline
score the underlying disease associated with the grafted vessel.
However, with only 202 patients, both the baseline and “residual”
score failed to predict events (30).
Head et al. (7) recently examined the impact of CR versus
IR on 3-year patient outcomes in the SYNTAX trial.
Consistent with the current study, this report demonstrated
that IR occurred more frequently in patients with more
complex disease at baseline (total occlusions, greater number
of lesions), and in the highest tertile (32) of the SS. In
contrast to the prior report, however, Head et al. (7) did not
find a significant difference in mortality and adverse isch-
emic events according to the extent of revascularization.
This difference between these 2 studies may reflect the more
precise categorization of IR in the present study, or differ-
ences in the patient populations.
The present study demonstrates for the first time that
quantification of the extent and complexity of residual
coronary stenoses remaining after PCI carries substantial
prognostic information. In this regard, since its first publi-
cation (9), the predictive value of the bSS (prior to PCI) has
(d)
p Value
a vs. b
p Value
a vs. c
p Value
a vs. d
p Value
b vs. c
p Value
b vs. d
p Value
c vs. d
p Value
All Groups
71) 0.11 0.001 0.001 0.16 0.01 0.24 0.001
9) 0.11 0.87 0.008 0.24 0.38 0.04 0.03
8) 0.03 0.43 0.003 0.24 0.53 0.07 0.02
46) 0.02 0.001 0.001 0.48 0.37 0.85 0.002
9) 0.42 0.93 0.03 0.59 0.29 0.05 0.18
53) 0.02 0.003 0.001 0.64 0.20 0.40 0.001
28) 0.65 0.008 0.003 0.01 0.006 0.73 0.002
110) 0.22 0.01 0.001 0.39 0.07 0.31 0.006
23) 0.06 0.28 0.001 0.49 0.10 0.02 0.001
13) 0.001 0.04 0.001 0.23 0.60 0.09 0.001
59) 0.06 0.02 0.001 0.71 0.25 0.41 0.007
11) 0.37 0.38 0.03 0.96 0.32 0.40 0.23
74) 0.04 0.001 0.001 0.71 0.07 0.13 0.001
63) 0.71 0.18 0.09 0.42 0.25 0.71 0.32
ry Intervention With Taxus and Cardiac Surgery score.SS >8
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June 12, 2012:2165–74 Residual SYNTAX Scorepatients (10–19). However, the role of the SS after PCI has
not previously been described. The present study demon-
strates that the rSS effectively risk-stratifies patients with
ACS undergoing an early invasive strategy with PCI. The
rSS had similar accuracy to predict and discriminate all
ischemic events compared with bSS, except for MI, for
which bSS was slightly superior. This finding is not surpris-
ing because most MIs were periprocedural. Baseline angio-
graphic characteristics therefore have more discriminatory
power to predict MI than residual untreated disease.
Predictably, a strong correlation was observed between
coronary artery disease severity at baseline and completeness
of revascularization. CR was infrequent in the 2 upper
tertiles of the bSS (Fig. 2). Because the rSS was a strong
predictor of adverse ischemic outcomes after PCI, the
Figure 3 Kaplan-Meier Curves Showing Cumulative Event Rates
(A) MACE, (B) death, (C) myocardial infarction, and (D) unplanned revascularizati
in incomplete revascularization compared with complete revascularization groups aknowledge that 90% of the patients in the 2 highest sbaseline SYNTAX tertiles will have IR suggests that alter-
native strategies of revascularization (such as CABG or
“hybrid” PCI  CABG) should be considered unless the
operator is confident that the level of ICR after PCI will be
low (i.e., rSS 2). Capodanno et al. (11) also reported
imilar results, finding that only 12% of patients with an SS
34 have CR after PCI. In this study, CR was also found
o be an independent predictor of survival (hazard ratio:
.55, 95% CI: 0.31 to 0.98, p 0.04), similar to our results.
hus, quantification and risk stratification of the extent and
omplexity of both baseline and residual CAD is essential
or full prognostic characterization.
Of interest, the “delta SS” from baseline to post-PCI,
epresenting the amount of disease “removed” by PCI, did
ot significantly vary according to the rSS (Table 1). This
ugh 1 Year
atified by tertiles of rSS score. Adverse ischemic events were significantly higher
ross all the rSS tertiles. Abbreviations as in Figure 1.Thro
on, str
nd acuggests in general that the net burden reduction in coro-
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Residual SYNTAX Score June 12, 2012:2165–74nary artery disease by PCI is comparable, regardless of
initial disease extent and complexity. Moreover, the propor-
tion of chronic total occlusions, severe calcification, and
complex bifurcations/trifurcations were disproportionately
represented in the higher rSS tertiles, lesions not favorable
to PCI. Small vessel and diffuse disease was also common in
all patients with IR. These findings suggest that IR was
most likely not by “choice,” but was rather consequent to
unfavorable anatomy for PCI. Aggressive secondary preven-
tion is therefore indicated in patients with substantial IR
after PCI.
Of note, CR (rSS  0) was associated with an improved
1-year prognosis in the intermediate- and high-risk bSS
tertiles of our cohort compared with “extensive” IR
(rSS8). Conversely, in the low-risk bSS tertile, complete-
ness of revascularization did not significantly influence the
1-year mortality rate. This finding suggests that baseline
Independent Predictors of 1-Year Ischemic OutcomesTable 5 Independent Predictors of 1-Year Ischemic Outcomes
Hazard Ratio
(95% Confidence Interval) p Value
All-cause death
rSS* 1.05 (1.03–1.08) 0.001
Age (per 10-year increase) 1.44 (1.10–1.89) 0.008
Insulin-treated diabetes 3.66 (2.04–6.57) 0.0001
Cardiac death
rSS* 1.06 (1.03–1.10) 0.001
Insulin-treated diabetes 4.89 (2.39–10.00) 0.0001
Renal dysfunction 2.23 (1.09–4.55) 0.03
Myocardial infarction
rSS* 1.02 (1.01–1.04) 0.003
Insulin-treated diabetes 1.41 (0.94–2.10) 0.09
Unplanned revascularization for
ischemia
rSS* 1.04 (1.02–1.05) 0.001
Age (10-year increase) 0.86 (0.78–0.96) 0.005
Insulin-treated diabetes 1.49 (1.02–2.17) 0.04
Baseline cardiac biomarker elevation
or ST-segment deviation
0.68 (0.53–0.86) 0.002
The following variables were included in each model: 1) for all-cause death: rSS (continuous
variable), age, diabetes, renal dysfunction, baseline troponin elevation, ST-segment deviation,
baseline white blood count; 2) for cardiac death: rSS (continuous variable), age, diabetes, and renal
dysfunction; 3) for myocardial infarction and unplanned revascularization: rSS (continuous vari-
able), age, male, diabetes, current smoker, renal dysfunction, baseline troponin elevation, ST-
segment deviation, prior myocardial infarction, prior percutaneous coronary intervention, baseline
white blood count, baseline hemoglobin, and type of stent (drug-eluting stent vs. bare-metal stent).
*Per SS point.
rSS  residual Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac
urgery score.
Receiver-Operating Characteristic Curve Analys1-Year Ischemic OutcomesTable 6 Re eiver-Op rating Characteristic C1-Year Ischemic Outcomes
AUC p Va
Death, all-cause 0.63 0.0
Death, cardiac 0.68 0.0
Myocardial infarction 0.57 0.0
Unplanned revascularization for ischemia 0.53 0.0
Major adverse cardiovascular events 0.55 0.0AUC  area under the curve; rSS  residual Synergy Between Percutaneousseverity of the coronary artery disease is an important
determinant of prognosis, but also that CR, when possible,
may be particularly important to improve patient survival in
those with high bSS. Conversely, relatively high survival
rates may be seen in patients with low bSS whether or not
CR is achieved. This finding is in line with the COURAGE
(Clinical Outcomes Utilizing Revascularization and Ag-
gressive Drug Evaluation) trial, which enrolled patients at
the lower end of the “patient-risk spectrum” (31).
In the present report, a relatively low proportion (40.4%)
of patients obtained CR. In the pivotal SYNTAX trial, CR
(defined by intent, not by quantitative measurement) was
achieved in 56.7% of patients in the PCI group and in
63.2% in the CABG group (p 0.005) (32). As the relative
results of PCI compared with CABG in the SYNTAX trial
varied according to the bSS (7), knowledge of the rSS might
provide further insights into which high-risk patients may
have an acceptable prognosis after PCI.
Study limitations. Several important limitations of the
present analysis should be discussed. First, ACUITY was a
trial performed in patients with moderate- and high-risk
ACS undergoing an early invasive strategy. Therefore,
although the SS has been validated in this patient popula-
tion (13), our conclusions apply to patients with similar
presentation and treatments. Second, the SS (and all its
components) was visually assessed by 3 interventional car-
diologists in whom good reproducibility for bSS evaluation
has been demonstrated (22). Nonetheless, the SS is based
on angiographic interpretation that has inherent limitations
(33), and the results may have varied if the SS was assessed
by less-trained readers, core lab technicians, by QCA
analysis (22), or derived from fractional flow reserve (34).
hird, the bSS and rSS are anatomic measures of revascu-
arization, and theoretically may be improved upon by
nowledge of ischemia or viability. However, such studies
ere not routinely available in patients with non–ST-
egment elevation ACS in the ACUITY trial in whom the
edian time from emergency room presentation to cathe-
erization was 24 h. Fourth, both the bSS and rSS often
qually weight narrowings in small versus large vessels, and
ith moderate versus severe stenoses; despite this shortcom-
ng, both scores have substantial prognostic utility. Addi-
ional studies are required to determine if the predictive
bility of these scores can be improved by a different
eighting algorithm. Finally, although we adjusted for
rSS andAnalysis of rSS and
Optimal Cutoff Sensitivity (%) Specificity (%)
5 52 69
5 57 68
2 59 52
4 42 65
2 56 52is ofurve
lue
01
01
01
5
01Coronary Intervention With Taxus and Cardiac Surgery score.
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may still be present. The results of this report should
therefore be considered hypothesis generating. Prospective
randomized trials are required to further evaluate the clinical
importance of achieving CR after PCI.
Conclusions
In moderate- and high-risk ACS patients with IR following
PCI, the newly described rSS is an independent predictor of
1-year mortality, cardiac mortality, MI, and unplanned
revascularization. The rSS has a good discriminatory power
for risk prediction of 1-year ischemic outcomes, is a useful
tool to stratify the extent and complexity of residual coro-
nary stenoses after PCI, and may identify patients who
could benefit from further revascularization. Specifically, in
our population of moderate- and high-risk ACS, an rSS8
was associated with an increased risk of 1-year mortality,
MI, and MACE.
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